Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. 4h-pyran-4-one, 3-hydroxy-2-methyl-, Gallium Salt (3:1)
2. Tris(3-hydroxy-2-methyl-4h-pyran-4-onato)gallium(iii)
3. Tris(maltolato)gallium(iii)
1. 108560-70-9
2. Gallium Tris(2-methyl-4-oxo-4h-pyran-3-olate)
3. 17lei49c2g
4. Gallium Maltolate [inci]
5. Gallium;2-methyl-4-oxopyran-3-olate
6. Db05420
7. B2699-054157
8. 3-bis[(2-methyl-4-oxopyran-3-yl)oxy]gallanyloxy-2-methylpyran-4-one
9. Gallium, Tris(3-(hydroxy-.kappa.o)-2-methyl-4h-pyran-4-onato-.kappa.o4)-, (oc-6-21)-
| Molecular Weight | 445.0 g/mol |
|---|---|
| Molecular Formula | C18H15GaO9 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 0 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 148 |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 200 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 4 |
Investigated for use/treatment in bladder cancer, lymphoma (unspecified), multiple myeloma, paget's disease, and prostate cancer.
Gallium maltolate is a novel orally active formulation of gallium, a semi-metallic element that is a potent inhibitor of ribonucleotide reductase, an enzyme that promotes tumor growth.Gallium is also known to concentrate in malignant tumors and sites of infection, and appears to favorably impact calcium deposition, making bones more resistant to degradation caused by cancer metastasis. Titan's novel product, gallium maltolate, may significantly expand the therapeutic potential of gallium by providing the advantages of enhanced bioavailablity, a potentially improved therapeutic profile and ease of administration.
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Gallium Maltolate is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Glioblastoma.
Lead Product(s): Gallium Maltolate,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: xCures
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Gallium Maltolate,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : xCures
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access to Gallium Maltolate (GaM)
Details : Gallium Maltolate is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Gallium maltolate is a orally administered drug is investigated for the treatment of pediatric glioblastoma multiforme patients and received Orphan Drug Designation from FDA.
Lead Product(s): Gallium Maltolate,Inapplicable
Therapeutic Area: Oncology Brand Name: GaM
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 13, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Gallium Maltolate,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IQ-AI Announces Orphan Drug Designation for GaM in Pediatric GBM
Details : Gallium maltolate is a orally administered drug is investigated for the treatment of pediatric glioblastoma multiforme patients and received Orphan Drug Designation from FDA.
Product Name : GaM
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 13, 2023

Details:
Gallium Maltolate (GaM) is the oral agent under study in IQAI's sponsored Phase I clinical trial being conducted at the Medical College of Wisconsin for the treatment of glioblastoma multiforme (GBM) brain cancer.
Lead Product(s): Gallium Maltolate,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: IQ-AI
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 28, 2023

Lead Product(s) : Gallium Maltolate,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : IQ-AI
Deal Size : Inapplicable
Deal Type : Inapplicable
IQ-AI Announces Orphan Drug Designation Status
Details : Gallium Maltolate (GaM) is the oral agent under study in IQAI's sponsored Phase I clinical trial being conducted at the Medical College of Wisconsin for the treatment of glioblastoma multiforme (GBM) brain cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 28, 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
29
PharmaCompass offers a list of Gallium Maltolate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Gallium Maltolate manufacturer or Gallium Maltolate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Gallium Maltolate manufacturer or Gallium Maltolate supplier.
A Gallium Maltolate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gallium Maltolate, including repackagers and relabelers. The FDA regulates Gallium Maltolate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gallium Maltolate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Gallium Maltolate supplier is an individual or a company that provides Gallium Maltolate active pharmaceutical ingredient (API) or Gallium Maltolate finished formulations upon request. The Gallium Maltolate suppliers may include Gallium Maltolate API manufacturers, exporters, distributors and traders.
Gallium Maltolate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gallium Maltolate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Gallium Maltolate GMP manufacturer or Gallium Maltolate GMP API supplier for your needs.
A Gallium Maltolate CoA (Certificate of Analysis) is a formal document that attests to Gallium Maltolate's compliance with Gallium Maltolate specifications and serves as a tool for batch-level quality control.
Gallium Maltolate CoA mostly includes findings from lab analyses of a specific batch. For each Gallium Maltolate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gallium Maltolate may be tested according to a variety of international standards, such as European Pharmacopoeia (Gallium Maltolate EP), Gallium Maltolate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gallium Maltolate USP).